Posts in News
Computer Aided Biology Pioneer Synthace Secures $25.6 Million in Series B Funding

Synthace Ltd., the company behind the leading cloud software platform for automating and improving the success rate of biological research and development, today announced the closing of a $25.6m Series B financing round led by Horizons Ventures with additional investment from Luminous Ventures, SOSV and select other individual and large family office investors. Synthace will use the new funds to drive continued product development and build upon its cell and gene therapy customer base to accelerate global awareness of its solutions.

Read More
NewsThe Synthace Teambiology
Synthace Named a 2018 Cool Vendor in Life Sciences by Gartner

Synthace Ltd., the company behind the leading cloud software platform for automating and improving the success rate of biological research and development, today announced it has been recognised in Gartner Inc.'s "Cool Vendors in Life Sciences" report published on June 6, 2018. The companies named in this report represent a look into the new and innovative vendors, products and services in the global Life Sciences market.

Read More
Synthace Appoints Bob Wiederhold as Chairman of its Board of Directors

Synthace Ltd., the company behind the leading software platform for automating and improving the success rate of biological research, has appointed Silicon Valley veteran Bob Wiederhold as Chairman of its board of Directors. Synthace operates at the intersection of biology and information technology (IT), and Wiederhold brings deep expertise and experience to the company as a result of building multiple successful IT start ups over the last 30 years.

Read More
NewsThe Synthace Team
Synthace collaborates with Oxford BioMedica, Cell and Gene Therapy Catapult and Stratophase

Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, has announced it has agreed, as lead partner, to enter into a collaboration agreement with a consortium of partners, including the Cell and Gene Therapy Catapult, Stratophase Ltd and Synthace Ltd. The agreement is a two-year £2 million collaboration project focused on gene and cell therapy manufacturing, co-funded by the UK’s innovation agency, Innovate UK.

Read More
NewsThe Synthace Team
Cambridge Consultants and Synthace launch new partnership

Product design and development firm Cambridge Consultants is joining forces with innovative software company Synthace in an ambitious bid to unlock the full potential of biology to address many of the global challenges facing the world. The partnership is aimed at boosting adoption of a powerful new platform for the engineering of biological systems – a crucial step towards groundbreaking developments such as truly personalised ‘precision’ medicine and the next generation of antibiotics.

Read More
NewsThe Synthace Team
Synthace enters into agreements to develop Antha drivers for liquid handling equipment

Synthace today announce at the O’Reilly Solid conference that the company has signed memorandums of understanding with Gilson Inc and CyBio Northern Europe Ltd relating to the creation of device drivers that integrate liquid handling equipment with the Antha protocol language. The first instruments for which Antha drivers will be written include the PIPETMAX® from Gilson and the CyBi®-FeliX 96/384 and GeneTheatre from CyBio.

Read More
NewsThe Synthace Team
Synthace announces the release of Antha, the open source language for biology

Antha is a language developed at Synthace to enable the rapid development, execution, and analysis of complex biological experiments. Synthace is now releasing this language to the global community so that everyone can benefit from robust, reproducible and shareable biological experimentation. Antha elements are not locked into equipment from any single manufacturer, and can be executing both using existing laboratory automation, or manually, enabling users in a wide range of environments.

Read More
NewsThe Synthace Team